Table Info

Table 1.

Hemodynamic definitions of pulmonary hypertension

Definition	Hemodynamic criteria	Clinical groups
PH	mPAP > 20 mmHg
Pre-capillary PH	mPAP > 20 mmHg PAWP ≤ 15 mmHg PVR > 2 WU	Group 1: PAH: idiopathic, heritable, associated with drugs/toxins, with concomitant diseases (including portal hypertension), with features of venous/capillary involvement Group 3: PH associated with lung diseases and/or hypoxia Group 4: PH due to pulmonary artery obstructions Group 5: PH with unclear and/or multifactorial mechanisms
Isolated post-capillary PH	mPAP > 20 mmHg PAWP > 15 mmHg PVR ≤ 2 WU	Group 2: PH associated with left heart disease Group 5: PH with unclear and/or multifactorial mechanisms
Combined pre- and post-capillary PH	mPAP > 20 mmHg PAWP > 15 mmHg PVR > 2 WU

Portopulmonary hypertension belongs to PAH (group 1 PH) characterized by precapillary PH in the absence of other causes of pre-capillary PH, such as chronic thrombo-embolic PH and PH associated with lung diseases. More details are reported in Humbert M, et al. Eur Heart J 2022 [20]. mPAP: mean pulmonary arterial pressure; PAH: pulmonary arterial hypertension; PAWP: pulmonary arterial wedge pressure; PH: pulmonary hypertension; PVR: pulmonary vascular resistance; WU: Wood units (1 WU = 80 dyn.s.cm^-5)

Note. Adapted with permission from “Portopulmonary hypertension: An unfolding story” by Thévenot T, Savale L, Sitbon O. Clin Res Hepatol Gastroenterol. 2020;45:101492 (https://www.sciencedirect.com/science/article/abs/pii/S221074012030187X?via%3Dihub). © 2020 Elsevier Masson SAS.

Declarations

Author contributions

TT: Writing—original draft, Validation, Writing—review & editing, Supervision. SR, AA, BAB, and HMD: Writing—original draft. JFDC: Visualization. All authors read and approved the submitted version.

Conflicts of interest

Prof. Jean François D. Cadranel is the Editorial Board Member of Exploration of Digestive Diseases, but he had no involvement in the journal review process of this manuscript. The other authors declare that they have no conflicts of interest.

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent to publication

Not applicable.

Availability of data and materials

Not applicable.

Funding

Not applicable.

Copyright

References

Mantz FA Jr, Craige E. Portal axis thrombosis with spontaneous portacaval shunt and resultant cor pulmonale. AMA Arch Pathol. 1951;52:91–7. [PubMed]

Yoshida EM, Erb SR, Pflugfelder PW, Ostrow DN, Ricci DR, Ghent CN, et al. Single-lung versus liver transplantation for the treatment of portopulmonary hypertension--a comparison of two patients. Transplantation. 1993;55:688–90. [PubMed]

DuBrock HM. Portopulmonary Hypertension: Management and Liver Transplantation Evaluation. Chest. 2023;164:206–14. [DOI] [PubMed]

Pavec JL, Souza R, Herve P, Lebrec D, Savale L, Tcherakian C, et al. Portopulmonary hypertension: survival and prognostic factors. Am J Respir Crit Care Med. 2008;178:637–43. [DOI] [PubMed]

Krowka MJ, Miller DP, Barst RJ, Taichman D, Dweik RA, Badesch DB, et al. Portopulmonary hypertension: a report from the US-based REVEAL Registry. Chest. 2012;141:906–15. [DOI] [PubMed]

Sithamparanathan S, Nair A, Thirugnanasothy L, Coghlan JG, Condliffe R, Dimopoulos K, et al. Survival in portopulmonary hypertension: Outcomes of the United Kingdom National Pulmonary Arterial Hypertension Registry. J Heart Lung Transplant. 2017;36:770–9. [DOI] [PubMed]

Savale L, Watherald J, Sitbon O. Portopulmonary Hypertension. Semin Respir Crit Care Med. 2017;38:651–61. [DOI] [PubMed]

Baiges A, Turon F, Simón-Talero M, Tasayco S, Bueno J, Zekrini K, et al. Congenital Extrahepatic Portosystemic Shunts (Abernethy Malformation): An International Observational Study. Hepatology. 2020;71:658–69. [DOI] [PubMed]

Krowka MJ, Fallon MB, Kawut SM, Fuhrmann V, Heimbach JK, Ramsay MAE, et al. International Liver Transplant Society Practice Guidelines: Diagnosis and Management of Hepatopulmonary Syndrome and Portopulmonary Hypertension. Transplantation. 2016;100:1440–52. [DOI] [PubMed]

10.

Raevens S, Geerts A, Steenkiste CV, Verhelst X, Vlierberghe HV, Colle I, et al. Hepatopulmonary syndrome and portopulmonary hypertension: recent knowledge in pathogenesis and overview of clinical assessment. Liver Int. 2015;35:1646–60. [DOI] [PubMed]

11.

Talwalkar JA, Swanson KL, Krowka MJ, Andrews JC, Kamath PS. Prevalence of spontaneous portosystemic shunts in patients with portopulmonary hypertension and effect on treatment. Gastroenterology. 2011;141:1673–9. [DOI] [PubMed]

12.

Hadengue A, Benhayoun MK, Lebrec D, Benhamou JP. Pulmonary hypertension complicating portal hypertension: prevalence and relation to splanchnic hemodynamics. Gastroenterology. 1991;100:520–8. [DOI] [PubMed]

13.

Roberts KE, Fallon MB, Krowka MJ, Brown RS, Trotter JF, Peter I, et al.; Pulmonary Vascular Complications of Liver Disease Study Group. Genetic risk factors for portopulmonary hypertension in patients with advanced liver disease. Am J Respir Crit Care Med. 2009;179:835–42. [DOI] [PubMed] [PMC]

14.

DuBrock HM, Cartin-Ceba R, Channick RN, Kawut SM, Krowka MJ. Sex Differences in Portopulmonary Hypertension. Chest. 2021;159:328–36. [DOI] [PubMed] [PMC]

15.

Simonneau G, Montani D, Celermajer DS, Denton CP, Gatzoulis MA, Krowka M, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J. 2019;53:1801913. [DOI] [PubMed] [PMC]

16.

Maron BA, Hess E, Maddox TM, Opotowsky AR, Tedford RJ, Lahm T, et al. Association of Borderline Pulmonary Hypertension With Mortality and Hospitalization in a Large Patient Cohort: Insights From the Veterans Affairs Clinical Assessment, Reporting, and Tracking Program. Circulation. 2016;133:1240–8. [DOI] [PubMed] [PMC]

17.

Maron BA, Brittain EL, Hess E, Waldo SW, Barón AE, Huang S, et al. Pulmonary vascular resistance and clinical outcomes in patients with pulmonary hypertension: a retrospective cohort study. Lancet Respir Med. 2020;8:873–84. [DOI] [PubMed] [PMC]

18.

Xanthouli P, Jordan S, Milde N, Marra A, Blank N, Egenlauf B, et al. Haemodynamic phenotypes and survival in patients with systemic sclerosis: the impact of the new definition of pulmonary arterial hypertension. Ann Rheum Dis. 2020;79:370–8. [DOI] [PubMed]

19.

Certain MC, Baron A, Turpin M, Ebstein N, Boucly A, Beurnier A, et al. Outcomes of cirrhotic patients with pre-capillary pulmonary hypertension and pulmonary vascular resistance between 2 and 3 Wood Units. Eur Respir J. 2022;60:2200107. [DOI] [PubMed]

20.

Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M, et al.; ESC/ERS Scientific Document Group. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2022;43:3618–731. [DOI] [PubMed]

21.

Téllez L, Guerrero A, Donate J, Rodríguez-Gandía MÁ, del Prado S, Tenes A, et al. The new diagnostic criteria of portopulmonary hypertension identify a group of patients with cirrhosis at high risk of death. J Hepatol. 2023;78:S79–80. [DOI]

22.

Cajigas HR, Burger CD, Cartin-Ceba R, DuBrock H, Swanson K, Vargas HE, et al. Portopulmonary Hypertension in Nontransplanted Patients: Results of the Largest US Single-Institution Registry. Mayo Clin Proc. 2022;97:2236–47. [DOI] [PubMed]

23.

Raevens S, Colle I, Reyntjens K, Geerts A, Berrevoet F, Rogiers X, et al. Echocardiography for the detection of portopulmonary hypertension in liver transplant candidates: an analysis of cutoff values. Liver Transpl. 2013;19:602–10. [DOI] [PubMed]

24.

Krowka MJ, Swanson KL, Frantz RP, McGoon MD, Wiesner RH. Portopulmonary hypertension: Results from a 10-year screening algorithm. Hepatology. 2006;44:1502–10. [DOI] [PubMed]

25.

Swanson KL, Wiesner RH, Nyberg SL, Rosen CB, Krowka MJ. Survival in portopulmonary hypertension: Mayo Clinic experience categorized by treatment subgroups. Am J Transplant. 2008;8:2445–53. [DOI] [PubMed]

26.

Fritz JS, Fallon MB, Kawut SM. Pulmonary vascular complications of liver disease. Am J Respir Crit Care Med. 2013;187:133–43. [DOI] [PubMed] [PMC]

27.

Savale L, Guimas M, Ebstein N, Fertin M, Jevnikar M, Renard S, et al. Portopulmonary hypertension in the current era of pulmonary hypertension management. J Hepatol. 2020;73:130–9. [DOI] [PubMed]

28.

Galiè N, Humbert M, Vachiery J, Gibbs S, Lang I, Torbicki A, et al.; ESC Scientific Document Group. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016;37:67–119. [DOI] [PubMed]

29.

Provencher S, Herve P, Jais X, Lebrec D, Humbert M, Simonneau G, et al. Deleterious effects of beta-blockers on exercise capacity and hemodynamics in patients with portopulmonary hypertension. Gastroenterology. 2006;130:120–6. [DOI] [PubMed]

30.

Deroo R, Trépo E, Holvoet T, Pauw MD, Geerts A, Verhelst X, et al. Vasomodulators and Liver Transplantation for Portopulmonary Hypertension: Evidence From a Systematic Review and Meta-Analysis. Hepatology. 2020;72:1701–16. [DOI] [PubMed]

31.

Hoeper MM, Halank M, Marx C, Hoeffken G, Seyfarth HJ, Schauer J, et al. Bosentan therapy for portopulmonary hypertension. Eur Respir J. 2005;25:502–8. [DOI] [PubMed]

32.

Sitbon O, Bosch J, Cottreel E, Csonka D, Groote Pd, Hoeper MM, et al. Macitentan for the treatment of portopulmonary hypertension (PORTICO): a multicentre, randomised, double-blind, placebo-controlled, phase 4 trial. Lancet Respir Med. 2019;7:594–604. [DOI] [PubMed]

33.

Makisalo H, Koivusalo A, Vakkuri A, Hockerstedt K. Sildenafil for portopulmonary hypertension in a patient undergoing liver transplantation. Liver Transpl. 2004;10:945–50. [DOI] [PubMed]

34.

Cartin-Ceba R, Halank M, Ghofrani H, Humbert M, Mattson J, Fritsch A, et al. Riociguat treatment for portopulmonary hypertension: a subgroup analysis from the PATENT-1/-2 studies. Pulm Circ. 2018;8:2045894018769305. [DOI] [PubMed] [PMC]

35.

Jose A, Kopras EJ, Shah SA, Elwing JM. Portopulmonary hypertension practice patterns after liver transplantation. Liver Transpl. 2023;29:365–76. [DOI] [PubMed] [PMC]

36.

Krowka MJ, Plevak DJ, Findlay JY, Rosen CB, Wiesner RH, Krom RA, et al. Pulmonary hemodynamics and perioperative cardiopulmonary-related mortality in patients with portopulmonary hypertension undergoing liver transplantation. Liver Transpl. 2000;6:443–50. [DOI] [PubMed]

37.

Valle KTD, Krowka MJ, Heimbach JK, Taner T, DuBrock HM. Temporal Trends in Portopulmonary Hypertension Model for End-stage Liver Disease Exceptions and Outcomes. Transplant Direct. 2022;8:e1410. [DOI] [PubMed] [PMC]

38.

DuBrock HM, Valle KTD, Krowka MJ. Mending the Model for End-Stage Liver Disease: An in-depth review of the past, present, and future portopulmonary hypertension Model for End-Stage Liver Disease exception. Liver Transpl. 2022;28:1224–30. [DOI] [PubMed]

39.

Savale L, Sattler C, Coilly A, Conti F, Renard S, Francoz C, et al. Long-term outcome in liver transplantation candidates with portopulmonary hypertension. Hepatology. 2017;65:1683–92. [DOI] [PubMed]

40.

Sadd CJ, Osman F, Li Z, Chybowski A, Decker C, Henderson B, et al. Long-term Outcomes and Survival in Moderate-severe Portopulmonary Hypertension After Liver Transplant. Transplantation. 2021;105:346–53. [DOI] [PubMed]

41.

Cartin-Ceba R, Burger C, Swanson K, Vargas H, Aqel B, Keaveny AP, et al. Clinical Outcomes After Liver Transplantation in Patients With Portopulmonary Hypertension. Transplantation. 2021;105:2283–90. [DOI] [PubMed]

42.

Verma S, Hand F, Armstrong MJ, Vos Md, Thorburn D, Pan T, et al. Portopulmonary hypertension: Still an appropriate consideration for liver transplantation? Liver Transpl. 2016;22:1637–42. [DOI] [PubMed]

43.

Berthelot P, Walker JG, Sherlock S, Reid L. Arterial changes in the lungs in cirrhosis of the liver--lung spider nevi. N Engl J Med. 1966;274:291–8. [DOI] [PubMed]

44.

Kennedy TC, Knudson RJ. Exercise-aggravated hypoxemia and orthodeoxia in cirrhosis. Chest. 1977;72:305–9. [DOI] [PubMed]

45.

DuBrock HM, Krowka MJ, Forde KA, Krok K, Patel M, Sharkoski T, et al. Clinical Impact of Intrapulmonary Vascular Dilatation in Candidates for Liver Transplant. Chest. 2018;153:414–26. [DOI] [PubMed] [PMC]

46.

Fallon MB, Krowka MJ, Brown RS, Trotter JF, Zacks S, Roberts KE, et al.; Pulmonary Vascular Complications of Liver Disease Study Group. Impact of hepatopulmonary syndrome on quality of life and survival in liver transplant candidates. Gastroenterology. 2008;135:1168–75. [DOI] [PubMed] [PMC]

47.

Rodríguez-Roisin R, Krowka MJ, Hervé P, Fallon MB; ERS Task Force Pulmonary-Hepatic Vascular Disorders (PHD) Scientific Committee. Pulmonary-Hepatic vascular Disorders (PHD). Eur Respir J. 2004;24:861–80. [DOI] [PubMed]

48.

Raevens S, Boret M, Fallon MB. Hepatopulmonary syndrome. JHEP Rep. 2022;4:100527. [DOI] [PubMed] [PMC]

49.

Zhao X, Kotha S, Nayyar D, Ma X, Lilly L, Castel H, et al. Physiologic changes in the hepatopulmonary syndrome before and after liver transplant: A longitudinal and predictor analysis. Hepatology. 2024;79:636–49. [DOI] [PubMed] [PMC]

50.

Rodríguez-Roisin R, Krowka MJ. Hepatopulmonary syndrome — a liver-induced lung vascular disorder. N Engl J Med. 2008;358:2378–87. [DOI] [PubMed]

51.

Degano B, Mittaine M, Hervé P, Rami J, Kamar N, Suc B, et al. Nitric oxide production by the alveolar compartment of the lungs in cirrhotic patients. Eur Respir J. 2009;34:138–44. [DOI] [PubMed]

52.

Nunes H, Lebrec D, Mazmanian M, Capron F, Heller J, Tazi KA, et al. Role of nitric oxide in hepatopulmonary syndrome in cirrhotic rats. Am J Respir Crit Care Med. 2001;164:879–85. [DOI] [PubMed]

53.

Liu L, Liu N, Zhao Z, Liu J, Feng Y, Jiang H, et al. TNF-α neutralization improves experimental hepatopulmonary syndrome in rats. Liver Int. 2012;32:1018–26. [DOI] [PubMed]

54.

Rabiller A, Nunes H, Lebrec D, Tazi KA, Wartski M, Dulmet E, et al. Prevention of gram-negative translocation reduces the severity of hepatopulmonary syndrome. Am J Respir Crit Care Med. 2002;166:514–7. [DOI] [PubMed]

55.

Sztrymf B, Rabiller A, Nunes H, Savale L, Lebrec D, Pape AL, et al. Prevention of hepatopulmonary syndrome and hyperdynamic state by pentoxifylline in cirrhotic rats. Eur Respir J. 2004;23:752–8. [DOI] [PubMed]

56.

Kawut SM, Krowka MJ, Forde KA, Al-Naamani N, Krok KL, Patel M, et al.; Pulmonary Vascular Complications of Liver Disease Study Group. Impact of hepatopulmonary syndrome in liver transplantation candidates and the role of angiogenesis. Eur Respir J. 2022;60:2102304. [DOI] [PubMed] [PMC]

57.

Baweja S, Kumari A, Negi P, Tomar A, Tripathi DM, Mourya AK, et al. Hepatopulmonary syndrome is associated with low sphingosine-1-phosphate levels and can be ameliorated by the functional agonist fingolimod. J Hepatol. 2023;79:167–80. [DOI] [PubMed]

58.

Ashraf MU, De A, Rose S. Fingolimod, a sphingosine-1-phosphate agonist for the treatment of hepatopulmonary syndrome: Queries and concerns. J Hepatol. 2023;79:e193–4. [DOI] [PubMed]

59.

Owen NE, Alexander GJ, Sen S, Bunclark K, Polwarth G, Pepke-Zaba J, et al. Reduced circulating BMP10 and BMP9 and elevated endoglin are associated with disease severity, decompensation and pulmonary vascular syndromes in patients with cirrhosis. EBioMedicine. 2020;56:102794. [DOI] [PubMed] [PMC]

60.

Yang W, Hu B, Wu W, Batra S, Blackburn MR, Alcorn JL, et al. Alveolar type II epithelial cell dysfunction in rat experimental hepatopulmonary syndrome (HPS). PLoS One. 2014;9:e113451. [DOI] [PubMed] [PMC]

61.

Abrams GA, Sanders MK, Fallon MB. Utility of pulse oximetry in the detection of arterial hypoxemia in liver transplant candidates. Liver Transpl. 2002;8:391–6. [DOI] [PubMed]

62.

Forde KA, Fallon MB, Krowka MJ, Sprys M, Goldberg DS, Krok KL, et al.; Pulmonary Vascular Complications of Liver Disease 2 Study Group. Pulse Oximetry Is Insensitive for Detection of Hepatopulmonary Syndrome in Patients Evaluated for Liver Transplantation. Hepatology. 2019;69:270–81. [DOI] [PubMed] [PMC]

63.

Raevens S, Colle I, Geerts A, Vlierberghe HV. Why Pulse Oximetry Is Inaccurate in Liver Cirrhosis: Ancient Knowledge. Hepatology. 2019;69:462–3. [DOI] [PubMed]

64.

Abrams GA, Nanda NC, Dubovsky EV, Krowka MJ, Fallon MB. Use of macroaggregated albumin lung perfusion scan to diagnose hepatopulmonary syndrome: a new approach. Gastroenterology. 1998;114:305–10. [DOI] [PubMed]

65.

Swanson KL, Wiesner RH, Krowka MJ. Natural history of hepatopulmonary syndrome: Impact of liver transplantation. Hepatology. 2005;41:1122–9. [DOI] [PubMed]

66.

Schenk P, Schöniger-Hekele M, Fuhrmann V, Madl C, Silberhumer G, Müller C. Prognostic significance of the hepatopulmonary syndrome in patients with cirrhosis. Gastroenterology. 2003;125:1042–52. [DOI] [PubMed]

67.

Umeda A, Tagawa M, Kohsaka T, Miyakawa T, Kawasaki K, Kitamura M, et al. Hepatopulmonary syndrome can show spontaneous resolution: possible mechanism of portopulmonary hypertension overlap? Respirolog. 11:120–3. [DOI] [PubMed]

68.

Raevens S, Fallon MB. Potential Clinical Targets in Hepatopulmonary Syndrome: Lessons From Experimental Models. Hepatology. 2018;68:2016–28. [DOI] [PubMed] [PMC]

69.

De BK, Dutta D, Pal SK, Gangopadhyay S, Baksi SD, Pani A. The role of garlic in hepatopulmonary syndrome: a randomized controlled trial. Can J Gastroenterol. 2010;24:183–8. [DOI] [PubMed] [PMC]

70.

Gupta S, Faughnan ME, Lilly L, Hutchison S, Fowler R, Bayoumi AM. Norfloxacin therapy for hepatopulmonary syndrome: a pilot randomized controlled trial. Clin Gastroenterol Hepatol. 2010;8:1095–8. [DOI] [PubMed]

71.

Yang W, Zhang J, Hu B, Wu W, Venter J, Alpini G, et al. The role of receptor tyrosine kinase activation in cholangiocytes and pulmonary vascular endothelium in experimental hepatopulmonary syndrome. Am J Physiol Gastrointest Liver Physiol. 2014;306:G72–80. [DOI] [PubMed] [PMC]

72.

Kawut SM, Ellenberg SS, Krowka MJ, Goldberg D, Vargas H, Koch D, et al. Sorafenib in Hepatopulmonary Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial. Liver Transpl. 2019;25:1155–64. [DOI] [PubMed] [PMC]

73.

Krowka MJ, Porayko MK, Plevak DJ, Pappas SC, Steers JL, Krom RA, et al. Hepatopulmonary syndrome with progressive hypoxemia as an indication for liver transplantation: case reports and literature review. Mayo Clin Proc. 1997;72:44–53. [DOI] [PubMed]

74.

Iyer VN, Swanson KL, Cartin-Ceba R, Dierkhising RA, Rosen CB, Heimbach JK, et al. Hepatopulmonary syndrome: favorable outcomes in the MELD exception era. Hepatology. 2013;57:2427–35. [DOI] [PubMed]

75.

Goldberg DS, Krok K, Batra S, Trotter JF, Kawut SM, Fallon MB. Impact of the hepatopulmonary syndrome MELD exception policy on outcomes of patients after liver transplantation: an analysis of the UNOS database. Gastroenterology. 2014;146:1256–65.e1. [DOI] [PubMed] [PMC]

76.

OPTN: Organ Procurement and Transplantation Network [Internet]. Health Resources and Services Administration; [cited 2021 Apr 28]. Available from: https://optn.transplant.hrsa.gov/media/1200/optn_policies.pdf

77.

Fallon MB, Mulligan DC, Gish RG, Krowka MJ. Model for end-stage liver disease (MELD) exception for hepatopulmonary syndrome. Liver Transpl. 2006;12:S105–7. [DOI] [PubMed]

78.

Aragon Pinto C, Iyer VN, Albitar HAH, Anderson A, Cajigas H, Simonetto DA, et al. Outcomes of liver transplantation in patients with hepatopulmonary syndrome in the pre and post-MELD eras: A systematic review. Respir Med Res. 2021;80:100852. [DOI] [PubMed]

79.

Kadry Z, Schaefer E, Krok K, Faust A, Stine JG, Schreibman IR, et al. Excellent outcomes with liver transplantation in hepatopulmonary syndrome across pre-transplant PaO₂ spectrum. JHEP Rep. 2021;3:100351. [DOI] [PubMed] [PMC]

80.

Jose A, Shah SA, Anwar N, Jones CR, McCormack FX, Sherman KE, et al. Predictors of outcomes following liver transplant in hepatopulmonary syndrome: An OPTN database analysis. Respir Med. 2021;190:106683. [DOI] [PubMed] [PMC]

81.

Pinto CA, Iyer V, Almodallal YA, Albitar H, Dubrock H, Cajigas H, et al. ICU and Hospital Outcomes in Patients with Hepatopulmonary Syndrome Undergoing Liver Transplantation. Lung. 2022;200:5–10. [DOI] [PubMed]

82.

Wu WK, Grogan WM, Ziogas IA, Patel YJ, Bacchetta M, Alexopoulos SP. Extracorporeal membrane oxygenation in patients with hepatopulmonary syndrome undergoing liver transplantation: A systematic review of the literature. Transplant Rev (Orlando). 2022;36:100693. [DOI] [PubMed]

83.

Fussner LA, Iyer VN, Cartin-Ceba R, Lin G, Watt KD, Krowka MJ. Intrapulmonary vascular dilatations are common in portopulmonary hypertension and may be associated with decreased survival. Liver Transpl. 2015;21:1355–64. [DOI] [PubMed]

84.

Aucejo F, Miller C, Vogt D, Eghtesad B, Nakagawa S, Stoller JK. Pulmonary hypertension after liver transplantation in patients with antecedent hepatopulmonary syndrome: a report of 2 cases and review of the literature. Liver Transpl. 2006;12:1278–82. [DOI] [PubMed]

85.

Krowka MJ. Hepatopulmonary Syndrome and Portopulmonary Hypertension: The Pulmonary Vascular Enigmas of Liver Disease. Clin Liver Dis (Hoboken). 2020;15:S13–24. [DOI] [PubMed] [PMC]

86.

Morrow CS, Kantor M, Armen RN. Hepatic hydrothorax. Ann Intern Med. 1958;49:193–203. [DOI] [PubMed]

87.

Norvell JP, Spivey JR. Hepatic hydrothorax. Clin Liver Dis. 2014;18:439–49. [DOI] [PubMed]

88.

Banini BA, Alwatari Y, Stovall M, Ogden N, Gershman E, Shah RD, et al. Multidisciplinary Management of Hepatic Hydrothorax in 2020: An Evidence-Based Review and Guidance. Hepatology. 2020;72:1851–63. [DOI] [PubMed]

89.

Badillo R, Rockey DC. Hepatic hydrothorax: clinical features, management, and outcomes in 77 patients and review of the literature. Medicine (Baltimore). 2014;93:135–42. [DOI] [PubMed] [PMC]

90.

Huang P, Chang Y, Yang C, Lee Y. The morphology of diaphragmatic defects in hepatic hydrothorax: thoracoscopic finding. J Thorac Cardiovasc Surg. 2005;130:141–5. [DOI] [PubMed]

91.

Benet A, Vidal F, Toda R, Siurana R, Virgala CMD, Richart C. Diagnosis of hepatic hydrothorax in the absence of ascites by intraperitoneal injection of 99m-Tc-Fluor colloid. Postgrad Med J. 1992;68:153. [DOI] [PubMed] [PMC]

92.

Osman KT, Abdelfattah AM, Mahmood SK, Elkhabiry L, Gordon FD, Qamar AA. Refractory Hepatic Hydrothorax Is an Independent Predictor of Mortality When Compared to Refractory Ascites. Dig Dis Sci. 2022;67:4929–38. [DOI] [PubMed]

93.

Thomas R, Jenkins S, Eastwood PR, Lee YCG, Singh B. Physiology of breathlessness associated with pleural effusions. Curr Opin Pulm Med. 2015;21:338–45. [DOI] [PubMed] [PMC]

94.

Xiol X, Castellví JM, Guardiola J, Sesé E, Castellote J, Perelló A, et al. Spontaneous bacterial empyema in cirrhotic patients: a prospective study. Hepatology. 1996;23:719–23. [DOI] [PubMed]

95.

Cadranel JD, Ollivier-Hourmand I, Cadranel J, Thevenot T, Zougmore H, Nguyen-Khac E, et al. International survey among hepatologists and pulmonologists on the hepatic hydrothorax: plea for recommendations. BMC Gastroenterol. 2023;23:305. [DOI] [PubMed] [PMC]

96.

Chen C, Shih C, Chou J, Liu Y, Hang L, Hsia T, et al. Outcome predictors of cirrhotic patients with spontaneous bacterial empyema. Liver Int. 2011;31:417–24. [DOI] [PubMed]

97.

Blackmore CC, Black WC, Dallas RV, Crow HC. Pleural fluid volume estimation: a chest radiograph prediction rule. Acad Radiol. 1996;3:103–9. [DOI] [PubMed]

98.

Light RW, Macgregor MI, Luchsinger PC, Ball WC Jr. Pleural effusions: the diagnostic separation of transudates and exudates. Ann Intern Med. 1972;77:507–13. [DOI] [PubMed]

99.

Matei D, Craciun R, Crisan D, Procopet B, Mocan T, Pasca S, et al. Hepatic Hydrothorax-An Independent Decompensating Event Associated with Long-Term Mortality in Patients with Cirrhosis. J Clin Med. 2021;10:3688. [DOI] [PubMed] [PMC]

100.

Chin A, Bastaich DR, Dahman B, Kaplan DE, Taddei TH, John BV. Refractory hepatic hydrothorax is associated with increased mortality with death occurring at lower MELD-Na compared to cirrhosis and refractory ascites. Hepatology. 2024;79:844–56. [DOI] [PubMed]

101.

Osman KT, Naritsin A, Amuchi B, Qamar AA. Liver transplantation for refractory hepatic hydrothorax is associated with a greater survival benefit compared to other complications of cirrhosis. Liver Transpl. 2024;30:142–50. [DOI] [PubMed]

102.

Cantey EP, Walter JM, Corbridge T, Barsuk JH. Complications of thoracentesis: incidence, risk factors, and strategies for prevention. Curr Opin Pulm Med. 2016;22:378–85. [DOI] [PubMed] [PMC]

103.

O’Leary JG, Rajender Reddy K, Tandon P, Biggins SW, Wong F, Kamath PS, et al. Increased Risk of ACLF and Inpatient Mortality in Hospitalized Patients with Cirrhosis and Hepatic Hydrothorax. Dig Dis Sci. 2021;66:3612–8. [DOI] [PubMed] [PMC]

104.

Dumortier J, Leprêtre J, Scalone O, Boillot O, Scoazec JY, Delafosse B, et al. Successful treatment of hepatic hydrothorax with octreotide. Eur J Gastroenterol Hepatol. 2000;12:817–20. [DOI] [PubMed]

105.

Ibrisim D, Cakaloglu Y, Akyuz F, Karadag A, Ozdil S, Besisik F, et al. Treatment of hepatic hydrothorax with terlipressin in a cirrhotic patient. Scand J Gastroenterol. 2006;41:862–5. [DOI] [PubMed]

106.

Kalambokis G, Economou M, Fotopoulos A, Bokharhii JA, Pappas C, Katsaraki A, et al. The effects of chronic treatment with octreotide versus octreotide plus midodrine on systemic hemodynamics and renal hemodynamics and function in nonazotemic cirrhotic patients with ascites. Am J Gastroenterol. 2005;100:879–85. [DOI] [PubMed]

107.

Bai Z, Méndez-Sánchez N, Romeiro FG, Mancuso A, Philips CA, Tacke F, et al.; Liver Cirrhosis-related Complications (LCC)-International Special Interest Group. Use of albumin infusion for cirrhosis-related complications: An international position statement. JHEP Rep. 2023;5:100785. [DOI] [PubMed] [PMC]

108.

Shojaee S, Khalid M, Kallingal G, Kang L, Rahman N. Repeat Thoracentesis in Hepatic Hydrothorax and Non-Hepatic Hydrothorax Effusions: A Case-Control Study. Respiration. 2018;96:330–7. [DOI] [PubMed]

109.

Orman ES, Lok ASF. Outcomes of patients with chest tube insertion for hepatic hydrothorax. Hepatol Int. 2009;3:582–6. [DOI] [PubMed] [PMC]

110.

Chen A, Massoni J, Jung D, Crippin J. Indwelling Tunneled Pleural Catheters for the Management of Hepatic Hydrothorax. Ann Am Thorac Soc. 2016;13:862–6. [DOI] [PubMed]

111.

Kniese C, Diab K, Ghabril M, Bosslet G. Indwelling Pleural Catheters in Hepatic Hydrothorax: A Single-Center Series of Outcomes and Complications. Chest. 2019;155:307–14. [DOI] [PubMed] [PMC]

112.

Cuk N, Melamed KH, Vangala S, Salah R, Miller WD, Swanson S, et al. Postoperative Trapped Lung After Orthotopic Liver Transplantation is a Predictor of Increased Mortality. Transpl Int. 2022;35:10387. [DOI] [PubMed] [PMC]

113.

Lui JK, Spaho L, Hakimian S, Devine M, Bui R, Touray S, et al. Pleural Effusions Following Liver Transplantation: A Single-Center Experience. J Intensive Care Med. 2021;36:862–72. [DOI] [PubMed]

114.

Chaaban T, Kanj N, Akl IB. Hepatic Hydrothorax: An Updated Review on a Challenging Disease. Lung. 2019;197:399–405. [DOI] [PubMed]

115.

Huang P, Kuo S, Chen J, Lee J. Thoracoscopic Mesh Repair of Diaphragmatic Defects in Hepatic Hydrothorax: A 10-Year Experience. Ann Thorac Surg. 2016;101:1921–7. [DOI] [PubMed]

116.

Hou F, Qi X, Guo X. Effectiveness and Safety of Pleurodesis for Hepatic Hydrothorax: A Systematic Review and Meta-Analysis. Dig Dis Sci. 2016;61:3321–34. [DOI] [PubMed]

117.

Gou X, Jia W, He C, Yuan X, Niu J, Xu J, et al. Hepatic hydrothorax does not increase the risk of death after transjugular intrahepatic portosystemic shunt in cirrhosis patients. Eur Radiol. 2023;33:3407–15. [DOI] [PubMed] [PMC]

118.

Ditah IC, Bawardy BFA, Saberi B, Ditah C, Kamath PS. Transjugular intrahepatic portosystemic stent shunt for medically refractory hepatic hydrothorax: A systematic review and cumulative meta-analysis. World J Hepatol. 2015;7:1797–806. [DOI] [PubMed] [PMC]

119.

Boike JR, Thornburg BG, Asrani SK, Fallon MB, Fortune BE, Izzy MJ, et al. North American Practice-Based Recommendations for Transjugular Intrahepatic Portosystemic Shunts in Portal Hypertension. Clin Gastroenterol Hepatol. 2022;20:1636–62.e36. [DOI] [PubMed] [PMC]

120.

Xiol X, Tremosa G, Castellote J, Gornals J, Lama C, Lopez C, et al. Liver transplantation in patients with hepatic hydrothorax. Transpl Int. 2005;18:672–5. [DOI] [PubMed]

121.

Sersté T, Moreno C, Francoz C, Razek WA, Paugham C, Belghitti J, et al. The impact of preoperative hepatic hydrothorax on the outcome of adult liver transplantation. Eur J Gastroenterol Hepatol. 2010;22:207–12. [DOI] [PubMed]

122.

Hung T, Tseng C, Tsai C, Tsai C, Tseng K, Hsieh Y. The long-term outcomes of cirrhotic patients with pleural effusion. Saudi J Gastroenterol. 2018;24:46–51. [DOI] [PubMed] [PMC]

123.

Osman KT, Cappuccio JM, Batarseh CI, Qamar AA. Hepatic hydrothorax is not associated with increased complications or poor survival after liver transplantation. Expert Rev Gastroenterol Hepatol. 2023;17:199–204. [DOI] [PubMed]

124.

Guidance to Liver Transplant Programs and the National Liver Review Board for: Adult MELD Exception Review [Internet]. Health Resources and Services Administration; [cited 2023 Mar 29]. Available from: https://optn.transplant.hrsa.gov/media/2847/liver_guidance_adult_meld_201706.pdf